Should I buy or sell Ultragenyx Pharmaceutical stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares. View RARE analyst ratings or view top-rated stocks .

What is Ultragenyx Pharmaceutical's stock price target for 2024?

10 equities research analysts have issued 1-year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price targets range from $48.00 to $133.00. On average, they expect the company's stock price to reach $91.55 in the next year. This suggests a possible upside of 107.5% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts .

How have RARE shares performed in 2024?

Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of the year. Since then, RARE shares have decreased by 7.8% and is now trading at $44.11. View the best growth stocks for 2024 here .

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RARE earnings forecast .

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.65) by $0.13. The biopharmaceutical company had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 369.54% and a negative net margin of 139.70%. Ultragenyx Pharmaceutical's revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.16) EPS.

What ETFs hold Ultragenyx Pharmaceutical's stock?

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , MFAM Small-Cap Growth ETF (MFMS) , Motley Fool Small-Cap Growth ETF (TMFS) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Motley Fool Mid-Cap Growth ETF (TMFM) , Virtus LifeSci Biotech Products ETF (BBP) , WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK) .

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com . Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE) , AbbVie (ABBV) , NVIDIA (NVDA) , Exelixis (EXEL) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Micron Technology (MU) , TG Therapeutics (TGTX) , GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM) .

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%), Woodstock Corp (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Camille L Bedrosian , Corazon (Corsee) D Sanders , Dennis Karl Huang , Emil D Kakkis, Emil D Kakkis , Erik Harris , John Richard Pinion , Karah Herdman Parschauer , Mardi Dier , Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg . View institutional ownership trends .

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RARE Stock Alerts

$44.11

+1.80 (+4.25%)

(As of 04/17/2024 ET)

Compare

Today's Range: $42.25
▼
$44.63
50-Day Range: $42.31
▼
$53.69
52-Week Range: $31.52
▼
$54.98

Volume: 890,196 shs
Average Volume: 765,974 shs
Market Capitalization: $3.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $91.55

Get Ultragenyx Pharmaceutical alerts:

Ultragenyx Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 107.5% Upside
$91.55 Price Target
Short Interest: Bearish
4.76% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.28
Upright™ Environmental Score
News Sentiment: 0.45
Based on 15 Articles This Week
Insider Trading: Selling Shares
$1.64 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.36) to ($5.12) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

122nd out of 914 stocks

Pharmaceutical Preparations Industry

39th out of 406 stocks

4.5

Analyst's Opinion

Consensus Rating
Ultragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Ultragenyx Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
4.76% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.
Short Interest Ratio / Days to Cover
Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Ultragenyx Pharmaceutical has recently increased by 3.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ultragenyx Pharmaceutical does not currently pay a dividend.
Dividend Growth
Ultragenyx Pharmaceutical does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ultragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Ultragenyx Pharmaceutical is -2.28.

1.9

News and Social Media Coverage

News Sentiment
Ultragenyx Pharmaceutical has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Ultragenyx Pharmaceutical this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,639,721.00 in company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.
Percentage Held by Institutions
97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.36) to ($5.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ultragenyx Pharmaceutical is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ultragenyx Pharmaceutical is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ultragenyx Pharmaceutical has a P/B Ratio of 13.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RARE Stock News Headlines

April 17, 2024 | americanbankingnews.com

Ultragenyx Pharmaceutical's (RARE) "Neutral" Rating Reaffirmed at Wedbush

April 16, 2024 | americanbankingnews.com

Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on Wednesday

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | msn.com

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

April 15, 2024 | markets.businessinsider.com

Ultragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick Facts

April 15, 2024 | finance.yahoo.com

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

April 12, 2024 | globenewswire.com

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

April 12, 2024 | finanznachrichten.de

Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | globenewswire.com

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

April 9, 2024 | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 7, 2024 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.7%

April 7, 2024 | cnn.com

Ultragenyx Pharmaceutical, Inc.

April 5, 2024 | markets.businessinsider.com

Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts

March 22, 2024 | globenewswire.com

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 22, 2024 | money.usnews.com

Ultragenyx Pharmaceutical Inc.

March 18, 2024 | markets.businessinsider.com

Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical

March 16, 2024 | finance.yahoo.com

RARE Apr 2024 50.000 put

March 15, 2024 | msn.com

3 Best Stocks to Buy Now, 3/15/2024, According to Top Analysts

March 14, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Cannabist Company Holdings (OtherCBSTF)

March 12, 2024 | finance.yahoo.com

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...

March 11, 2024 | msn.com

What’s next for AAV gene therapies in 2024?

March 11, 2024 | finance.yahoo.com

Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)

March 9, 2024 | seekingalpha.com

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

February 27, 2024 | globenewswire.com

Ultragenyx to Participate at Investor Conferences in March

February 23, 2024 | globenewswire.com

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2024 | finanznachrichten.de

Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

See More Headlines

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RARE
CUSIP: N/A
CIK: 1515673
Web: www.ultragenyx.com
Phone: (415) 483-8800
Fax: 415-483-8810
Employees: 1,276
Year Founded: 2010

Price Target and Rating

Average Stock Price Target: $91.55
High Stock Price Target: $133.00
Low Stock Price Target: $48.00
Potential Upside/Downside: +107.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-606,640,000.00
Net Margins: -139.70%
Pretax Margin: -140.12%
Return on Equity: -369.54%
Return on Assets: -44.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.61
Quick Ratio: 2.49

Sales & Book Value

Annual Sales: $434.25 million
Price / Sales: 8.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.35 per share
Price / Book: 13.17

Miscellaneous

Outstanding Shares: 82,300,000
Free Float: 76,704,000
Market Cap: $3.63 billion
Optionable: Optionable
Beta: 0.65

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Emil D. Kakkis M.D. (Age 64)
Ph.D., Founder, President, CEO & Director
Comp: $1.37M
Mr. John Richard Pinion II (Age 58)
Chief Quality Operations Officer & Executive VP of Translational Sciences
Comp: $806.19k
Mr. Erik Harris (Age 53)
Executive VP & Chief Commercial Officer
Comp: $848.24k
Mr. Howard Horn (Age 45)
Executive VP of Corporate Strategy & CFO
Mr. Theodore A. Huizenga (Age 53)
Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Dennis Karl Huang (Age 59)
Chief Technical Operations Off., Gene Therapy Research & Development and Executive VP
Comp: $331.33k
Ms. Danielle Keatley
Senior Director of Investor Relations & Corporate Communications
Ms. Karah Herdman Parschauer J.D. (Age 46)
Chief Legal Officer & Executive VP of Corporate Affairs
Comp: $595.01k
Mr. Ernie W. Meyer (Age 59)
Chief Human Resources Officer & Executive VP
Mr. Thomas R. Kassberg (Age 64)
Chief Business Officer & Executive VP
Comp: $714.84k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.
What is Ultragenyx Pharmaceutical's stock price target for 2024?: 10 equities research analysts have issued 1-year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price targets range from $48.00 to $133.00. On average, they expect the company's stock price to reach $91.55 in the next year. This suggests a possible upside of 107.5% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.
How have RARE shares performed in 2024?: Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of the year. Since then, RARE shares have decreased by 7.8% and is now trading at $44.11.
View the best growth stocks for 2024 here.
When is Ultragenyx Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RARE earnings forecast.
How were Ultragenyx Pharmaceutical's earnings last quarter?: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.65) by $0.13. The biopharmaceutical company had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 369.54% and a negative net margin of 139.70%. Ultragenyx Pharmaceutical's revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.16) EPS.
What ETFs hold Ultragenyx Pharmaceutical's stock?: ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust NYSE Arca Biotechnology Index Fund (FBT), Motley Fool Mid-Cap Growth ETF (TMFM), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK).

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?: Ultragenyx Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million.
What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?: 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Ultragenyx Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).
Who are Ultragenyx Pharmaceutical's major shareholders?: Ultragenyx Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%), Woodstock Corp (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends.
How do I buy shares of Ultragenyx Pharmaceutical?: Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RARE) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial